Associate Professor University of British Columbia Hospital
Disclosure information not submitted.
Renal artery denervation, promoted incorrectly as a potential cure for hypertension, had a spectacular rise and subsequent fall in 2014. Since that time further data has been generated refining the role in hypertension management, more optimal patient selection, and demonstrating safety. FDA approval for devices using radiofrequency, focussed ultrasound and periadvential injection are imminent or in process. In addition sympathetic denervation is being explored for other common diseases such as diabetes. New data will be presented and the 3 major technologies reviewed. By no means will renal denervation be applicable to every hypertensive patient, nevertheless even a small percentage of hypertensive patients represents a large patient population. If interventional radiology does not get involved in this evolving story, we risk being excluded from ultimately common procedures.
Learning Objectives:
Identify the reasons renal artery denervation is being reconsidered as a treatment in the management of refractory hypertension
Describe renal artery denervation using radiofrequency ablation, focussed ultrasound ablation and periadventiial drug delivery.
Describe the potential role of renal artery denervation in the management of hypertension
.png)
.png)
.png)
.jpg)
.png)
.png)
.png)
.jpg)
.jpg)